Viatris Wants To Rein In Neurim's Melatonin Patent Damages
A Viatris subsidiary has argued that a London court should limit the damages it owes to rival Neurim over sales of its generic sleep aid to patients over the age of...To view the full article, register now.
Already a subscriber? Click here to view full article